Switzerland’s Actelion Pharmaceuticals Ltd. has been a reluctant M&A target in the past, unmoved by unconfirmed approaches from several big pharma companies that most recently included Shire PLC in 2015, but this time around worries about growing competition to its key pulmonary arterial hypertension (PAH) therapies might make it more receptive to a deep-pocketed suitor.
Actelion Could Succumb To Big Pharma's Charms
News that Europe’s largest biotech Actelion is in preliminary discussions with Johnson & Johnson about a transaction has been viewed favourably by investors, and could see the return of mega-merger activity to other big pharma companies.
More from Deals
More from Business
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
• By
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.
• By
Restructuring Edition: ESSA and Elevation are reviewing strategic alternatives after trial failures, but each has an investor urging them to liquidate. Also, Third Harmonic and Vincerx are winding down, while Keros and Tempest are assessing options, but Opthea and OPM are cutting jobs.